7 ways Viagra changed how drugs are marketed
The inside story on a campaign for the ages, as told by the individuals who worked on it.
DTC
Five things for pharma marketers to know: Wednesday, September 14, 2016
Patients who ask for a prescription after seeing an ad are more likely to get one; Mylan’s executive pay is now under scrutiny
Five things for pharma marketers to know: Monday, September 12, 2016
Some drugmakers employ unsettling ads; Teva said the FDA may grant quick review for generic EpiPen; Sanofi and Google’s Verily partner in diabetes
MM&M’s top 5 stories in August 2016
Shire hires Jennifer Aniston for a disease awareness campaign; critics argue that the direct-to-consumer ads for Opdivo are misleading, while Merck’s Keytruda takes the lead in first-line cancer
DTC ads for Opdivo face further backlash
Critics say the direct-to-consumer ad for the immuno-oncology therapy is misleading.
Five things for pharma marketers to know: Wednesday, August 10, 2016
A new bill exempting CME reporting gains physician support; NYT op-ed calls Opdivo DTC ad “misleading;” Valeant to sell non-core assets worth $8 billion
Five things for pharma marketers to know: Tuesday, June 14, 2016
Physicians debate DTC tax write-off; Novo Nordisk’s Victoza shows 13% benefit in reducing cardiovascular risks; Shire to acquire Pfizer bowel drug
Industry criticizes FDA’s proposed DTC studies
Pharma companies took issue with the methodology for the FDA’s proposed studies of advertising tactics.
Five things for pharma marketers to know: Monday, May 16, 2016
Pfizer buys Anacor; Harvard Medical School loosens rules for faculty ties to pharma; Vermont poised to pass price transparency bill
Lobbyists argue DTC ad tax deduction may be a casualty of reform
Advertising lobbyist said eliminating the DTC ad tax deduction is a real threat to the industry.
